Towards subunit-specific proteasome inhibitors: Synthesis and evaluation of peptide α',β'-epoxyketones

Chemistry and Biology

Volumn 6, Issue 11, 1999, Pages 811-822

  Elofsson, Mikael ^a,c   Splittgerber, Ute ^a   Myung, Jayhyuk ^a   Mohan, Royce ^a   Crews, Craig M ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Epoxyketone; Inhibitor; Proteasome; Subunit specificity

Indexed keywords

CATALYTIC ACTIVITY; CHYMOTRYPSIN; ENZYME INHIBITOR; ENZYME SYNTHESIS; EPOXYKETONE; MOLECULAR PROBE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN HYDROLYSIS; TRYPSIN;

EID: 0033230405     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80128-8     Document Type: Article

References (46)

1. Tanaka, K. (1998). Proteasomes: Structure and biology. J. Biochem. 123, 195-204.
2. Goldberg, A.L., Akopian, T.N., Kisselev, A.F., Lee, D.H. & Rohrwild, M. (1997). New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol. Chem. 378, 131-140.
3. King, R.W., Deshaies, R.J., Peters, J.-M. & Kirschner, M.W. (1996). How proteolysis drives the cell cycle. Science 274, 1652-1659.
4. Palombella, V.J., Rando, O.J., Goldberg, A.L. & Maniatis, T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-κ B1 precursor protein and the activation of NF-κB. Cell 78, 773-785.
5. Tanaka, K. & Kasahara, M. (1998). The MHC class I ligand-generating system: Roles of the immunoproteasomes and the interferon-γ-inducible proteasome activator PA28. Immunol. Rev. 163, 161-176.
6. Löwe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W. & Huber, R. (1995). Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 268, 533-539.
7. Groll, M., et al., & Huber, R. (1997). Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386, 463-471.
8. Seemüller, E., Lupas, A., Stock, D., Löwe, J., Huber, R. & Baumeister, W. (1995). Proteasome from Thermoplasma acidophilum: A threonine protease. Science 268, 579-582.
9. Peters, J.M., Cejka, Z., Harris, J.R., Kleinschmidt, J.A. & Baumeister, W. (1993). Structural features of the 26S proteasome complex. J. Mol. Biol. 234, 932-937.
10. Gray, C.W., Slaughter, C.A. & DeMartino, G.N. (1994). PA28 activator protein forms regulatory caps on proteasome stacked rings. J. Mol. Biol. 236, 7-15.
11. Orlowski, M., Cardozo, C. & Michaud, C. (1993). Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32, 1563-1572.
12. Lee, D.H. & Goldberg, A.L. (1998). Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403.
13. Rolfe, M., Chiu, M.I. & Pagano, M. (1997). The ubiquitin-mediated proteolytic pathway as a therapeutic area. J. Mol. Med. 75, 5-17.
14. Spataro, V., Norbury, C. & Harris, A.L. (1998). The ubiquitin-proteasome pathway in cancer. Br. J. Cancer 77, 448-455.
15. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J. & Schreiber, S.L. (1995). Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731.
16. Adams, J., et al., & Stein, R.L. (1998). Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338.
17. Rock, K.L., et al., & Goldberg, A.L. (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771.
18. McCormack, T., et al., & Dick, L. (1997). Active site-directed inhibitors of Rhodococcus 20S proteasome. Kinetics and mechanism. J. Biol. Chem. 272, 26103-26109.
19. Figueiredo-Pereira, M.E., Berg, K.A. & Wilk, S. (1994). A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63, 1578-1581.
20. Spaltenstein, A., et al., & Crouch, R. (1996). Design and synthesis of novel protease inhibitors. Tripeptide α′,β′-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett. 37, 1343-1346.
21. Sin, N., Kim, K., Elofsson, M., Meng, L., Auth, H. & Crews, C.M. (1999). Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett. 9, 2283-2288.
22. Meng, L., Mohan, R., Kwok, B.H.B., Elofsson, M., Sin, N. & Crews, C.M. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl Acad. Sci. USA 96, 10403-10408.
23. Meng, L., Kwok, B.H.B., Sin, N. & Crews, C.M. (1999). Eponemycin exerts its antitumor effect through inhibition of proteasome function. Cancer Res. 59, 2798-2801.
24. Lynas, J.F., Harriott, P., Healy, A., McKervey, M.A. & Walker, B. (1998). Inhibitors of the chymotrypsin-like activity of proteasome based on di- And tri-peptidyl α-keto aldehydes (glyoxals). Bioorg. Med. Chem. Lett. 8, 373-378.
25. Bogyo, M., Shin, S., McMaster, J.S. & Ploegh, H.L. (1998). Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5, 307-320.
26. Bogyo, M., McMaster, J.S., Gaczynska, M., Tortorella, D., Goldberg, A.L. & Ploegh, H. (1997). Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629-6634.
27. Palmer, J.T., Rasnick, D., Klaus, J.L. & Brömme, D. (1995). Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38, 3193-3196.
28. Ostrowska, H., Wojcik, C., Omura, S. & Worowski, K. (1997). Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem. Biophys. Res. Commun. 234, 729-732.
29. Geier, E., et al., & Niedermann, G. (1999). A giant protease with potential to substitute for some functions of the proteasome. Science 283, 978-981.
30. Craiu, A., et al., & Rock, K.L. (1997). Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272, 13437-13445.
31. Loidl, G., Groll, M., Musiol, H.-J., Huber, R. & Moroder, L. (1999). Bivalency as a principle for proteasome inhibition. Proc. Natl Acad. Sci. USA 96, 5418-5422.
32. Loidl, G., Groll, M., Musiol, H.-J., Ditzel, L., Huber, R. & Moroder, L. (1999). Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol. 6, 197-204.
33. Hanada, M., et al. & Oki, T. (1992). Epoxomicin, a new antitumor agent of microbial origin. J. Antibiotics 45, 1746-1752.
34. Sugawara, K., et al. & Oki, T. (1990). Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J. Antibiotics 43, 8-18.
35. Sin, N., Meng, L., Auth, H. & Crews, C.M. (1998). Eponemycin analogs: Synthesis and use as probes of angiogenesis. Bioorg. Med. Chem. 6, 1209-1217.
36. Crews, C.M. & Splittgerber, U. (1999). Chemical genetics: Exploring and controlling cellular processes with chemical probes. Trends Biochem. Sci. 24, 317-320.
37. Fields, G.B. & Noble, R.L. (1990). Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161-214.
38. Grant, G.A. (1992). Synthetic peptides. In A User's Guide. (Grant, GA, ed.) W.H. Freeman and Company, New York, USA.
39. Carpino, L.A. (1993). 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 115, 4397-4398.
40. Carpino, L.A., Ei-Faham, A. & Albericio, F. (1994). Racemization studies during solid-phase peptide synthesis using azabenzotriazole-based coupling reagents. Tetrahedron Lett. 35, 2279-2282.
41. Roush, W.R., Gonzalez, F.V., McKerrow, J.H. & Hansell, E. (1999). Design and synthesis of dipeptidyl α′,β′-epoxyketones, potent and irreversible inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett. 8, 2809-2812.
42. Grabbe, S., Steinert, M., Mahnke, K., Schwartz, A., Luger, T.A. & Schwarz, T. (1996). Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. J. Clin. Invest. 98, 1158-1164.
43. McGuire, M.J. & DeMartino, G.N. (1986). Purification and characterization of a high molecular weight proteinase (macropain) from human erythrocytes. Biochim. Biophys. Acta 873, 279-289.
44. McGuire, M.J., McCullough, M.L., Croall, D.E., & DeMartino, G.N. (1989). The high molecular weight multicatalytic proteinase, macropain, exists in a latent form in human erythrocytes. Biochim. Biophys. Acta 995, 181-186.
45. Morrison, J.F. & Walsh, C.T. (1988). The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301.
46. Kehren, J., et al., & Nicolas, J.F. (1999). Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity. J. Exp. Med. 189, 779-786.